Natrix Separations Inc. today announced development agreements with Merck, known as MSD outside the United States and Canada, and Sanofi to advance Natrix’s new membrane-based Protein A platform for antibody purification. The Natrix Protein A platform is expected to pave the way for a new generation of more flexible, highly-productive single-use based biologics production facilities for both batch and continuous processes. The platform is predicted to increase purification productivity by a factor of up to 10x, while reducing both cost…

MilliporeSigma today announced that it has entered into a set of agreements with Evotec AG, whereby Evotec AG will provide screening services for Merck’s collection of genetic reagents such as CRISPR and shRNA libraries. Combining access to these libraries with Evotec’s screening expertise offers an accelerated pathway to explore and identify new drug targets. “Drug discovery starts with the identification of new targets, a process that can be time- and labor-intensive,” said Theresa Creasey, Head of Applied Solutions Strategic Marketing &…